Abstract
Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) are two devastating diseases that are currently incurable. Epidemiological, clinical and pathological evidence has confirmed the co-existence of these two disorders. Moreover, there has been promising progress made in the identification of the pathological linkage between T2DM and AD in the last decade. Hence, developing common treatment strategies for these diseases is important. Currently, enzyme targeting is a potential strategy to cure many diseases. In this communication, we tried to summarize the single enzymetargeted therapeutic approach for the treatment of AD and T2DM. This field of research continues to be active and progressive in identifying many promising enzymes that are involved in both diseases. Based on this review article, we also believe that enzyme inhibition is a promising and reliable strategy for the treatment of many incurable diseases. In the future, we expect that the scientific community will be able to develop common enzyme inhibitors for the treatment of both AD and T2DM.
Keywords: Alzheimer’s disease, diabetes, enzymes, drug therapy, endocrine disorders.
CNS & Neurological Disorders - Drug Targets
Title:Alzheimer’s and Type 2 Diabetes Treatment via Common Enzyme Targeting
Volume: 13 Issue: 2
Author(s): Nasimudeen R. Jabir, Mohammad A. Kamal, Adel Mohammad Abuzenadah, Siew Hua Gan, Mohammed Nabil Alama, Saleh S. Baeesa and Shams Tabrez
Affiliation:
Keywords: Alzheimer’s disease, diabetes, enzymes, drug therapy, endocrine disorders.
Abstract: Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) are two devastating diseases that are currently incurable. Epidemiological, clinical and pathological evidence has confirmed the co-existence of these two disorders. Moreover, there has been promising progress made in the identification of the pathological linkage between T2DM and AD in the last decade. Hence, developing common treatment strategies for these diseases is important. Currently, enzyme targeting is a potential strategy to cure many diseases. In this communication, we tried to summarize the single enzymetargeted therapeutic approach for the treatment of AD and T2DM. This field of research continues to be active and progressive in identifying many promising enzymes that are involved in both diseases. Based on this review article, we also believe that enzyme inhibition is a promising and reliable strategy for the treatment of many incurable diseases. In the future, we expect that the scientific community will be able to develop common enzyme inhibitors for the treatment of both AD and T2DM.
Export Options
About this article
Cite this article as:
Jabir R. Nasimudeen, Kamal A. Mohammad, Abuzenadah Mohammad Adel, Gan Hua Siew, Alama Nabil Mohammed, Baeesa S. Saleh and Tabrez Shams, Alzheimer’s and Type 2 Diabetes Treatment via Common Enzyme Targeting, CNS & Neurological Disorders - Drug Targets 2014; 13 (2) . https://dx.doi.org/10.2174/18715273113126660145
DOI https://dx.doi.org/10.2174/18715273113126660145 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design Topiramate in the New Generation of Drugs: Efficacy in the Treatment of Alcoholic Patients
Current Pharmaceutical Design Editorial (Thematic Issue: Metabolic Syndrome in Pregnancy)
Current Pharmaceutical Biotechnology Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio as Biomarkers for Cardiovascular Surgery Procedures: A Literature Review
Reviews on Recent Clinical Trials The Effects of CCRC on Cognition and Brain Activity in aMCI Patients: A Pilot Placebo Controlled BOLD fMRI Study
Current Alzheimer Research Role of Novel Drug Delivery Systems in Coronavirus Disease-2019 (COVID-19): Time to Act Now
Current Drug Delivery Cortisol Regulation in the Metabolic Syndrome. A Novel Therapeutic Approach
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Interplay of Marine Exposure in Gestational Diabetes
Current Women`s Health Reviews Pancreatic β-Cells and Type 2 Diabetes Development
Current Diabetes Reviews Subject Index to Volume 4
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Nutritional Interventions and Primary Prevention of Type 2 Diabetes
Current Nutrition & Food Science The Impact of the Emerging Genomics Data on the Management of Agerelated Phenotypes in the Context of Cellular Senescence
Current Drug Targets Regulation of Angiogenesis and Angiogenic Factors by Cardiovascular Medications
Current Pharmaceutical Design Feasibility of a Scale-down Production of [<sup>68</sup>Ga]Ga-NODAGA-Exendin-4 in a Hospital Based Radiopharmacy
Current Radiopharmaceuticals Menin, Histone H3 Methyltransferases, and Regulation of Cell Proliferation: Current Knowledge and Perspective
Current Molecular Medicine Glucagon and Glucagon-like Peptide-1 Receptors: Promising Therapeutic Targets for an Effective Management of Diabetes Mellitus
Current Pharmaceutical Design Editorial (Thematic Issue: Sex, Environment, Physical Activity, Diet, and Obesity in Cardiovascular Disease Risk)
Current Vascular Pharmacology Serum Interleukin Levels and Insulin Resistance in Major Depressive Disorder
CNS & Neurological Disorders - Drug Targets Islet Purification for Clinical Islet Transplantation
Current Tissue Engineering (Discontinued) Structural and Functional Characterization of Pathogenic Non- Synonymous Genetic Mutations of Human Insulin-Degrading Enzyme by In Silico Methods
CNS & Neurological Disorders - Drug Targets